Ceritinib Patent Expiration
Ceritinib is Used for treating cancers mediated by anaplastic lymphoma kinase (ALK). It was first introduced by Novartis Pharmaceuticals Corp
Ceritinib Patents
Given below is the list of patents protecting Ceritinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zykadia | US12357630 | Ceritinib Formulation | Dec 13, 2037 | Novartis |
| Zykadia | US8703787 | Methods of using ALK inhibitors | Feb 02, 2032 | Novartis |
| Zykadia | US9309229 | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine | Jan 18, 2032 | Novartis |
| Zykadia | US8039474 | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | Jun 29, 2030 | Novartis |
| Zykadia | US8039479 | Compounds and compositions as protein kinase inhibitors | Jun 29, 2030 | Novartis |
| Zykadia | US7964592 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Apr 29, 2028 | Novartis |
| Zykadia | US8377921 | Compounds and compositions as protein kinase inhibitors | Nov 20, 2027 | Novartis |
| Zykadia | US8399450 | Compounds and compositions as protein kinase inhibitors | Nov 20, 2027 | Novartis |
| Zykadia | US7893074 | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr 25, 2026
(Expired) | Novartis |
| Zykadia | US8188276 | 2,4-pyrimidinediamine compounds and their uses |
Jan 31, 2023
(Expired) | Novartis |
| Zykadia | US8835430 | 2,4-pyrimidinediamine compounds and their uses |
Jan 31, 2023
(Expired) | Novartis |
| Zykadia | US9018204 | 2,4-pyrimidinediamine compounds and their uses |
Jan 31, 2023
(Expired) | Novartis |
| Zykadia | US9416112 | 2,4-pyrimidinediamine compounds and their uses |
Jan 31, 2023
(Expired) | Novartis |
| Zykadia | US7153964 | Pyrimidine compounds |
Feb 26, 2021
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Ceritinib's patents.
Latest Legal Activities on Ceritinib's Patents
Given below is the list recent legal activities going on the following patents of Ceritinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent | 23 Sep, 2024 | US9416112 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 04 Sep, 2024 | US8399450 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Aug, 2024 | US8377921 |
| Expire Patent Critical
| 01 Jul, 2024 | US8188276(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 08 Apr, 2024 | US9416112 |
| Email Notification Critical
| 15 Feb, 2024 | US8188276(Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical
| 15 Feb, 2024 | US8188276(Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical
| 14 Feb, 2024 | US9416112 |
| Email Notification Critical
| 14 Feb, 2024 | US9416112 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 13 Feb, 2024 | US8835430(Litigated) |
Ceritinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ceritinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Giselle Sholler | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | M.D. Anderson Cancer Center | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1 |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | H. Lee Moffitt Cancer Center and Research Institute | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1 |
| Molecular Profiling of Advanced Soft-tissue Sarcomas | Institut National de la Santé Et de la Recherche Médicale, France | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| Next Generation Personalized Neuroblastoma Therapy | Yael P Mosse | NA |
TERMINATED
(Mar 1, 2026)
| PHASE1 |